Insulinoma

1. Clinical Overview

Summary

Insulinoma is a rare functioning neuroendocrine tumour (NET) of the pancreatic beta-cells that secretes insulin autonomously, causing recurrent episodes of fasting hypoglycaemia. It is the most common functioning pancreatic neuroendocrine tumour (PNET), with an incidence of 1-4 per million per year. [1,7] The pathognomonic presentation is Whipple's Triad: symptoms of hypoglycaemia, documented low blood glucose, and relief with glucose administration. [18]

Insulinomas produce insulin independent of physiological glucose feedback, leading to inappropriate hyperinsulinaemia during fasting states. This distinguishes them from reactive (post-prandial) hypoglycaemia. [7] The gold standard diagnostic test is the 72-hour supervised fast, which demonstrates inappropriately elevated insulin and C-peptide levels in the presence of hypoglycaemia. [1,2,3]

Over 90% of insulinomas are benign, solitary, and less than 2 cm in diameter. [4,7] Approximately 5-10% are associated with Multiple Endocrine Neoplasia Type 1 (MEN1), where they may be multiple. [7,8] Malignancy occurs in 5-10% of cases, defined by the presence of metastases (most commonly to liver or regional lymph nodes). [13,14]

Surgical resection (enucleation or partial pancreatectomy) is the definitive treatment and achieves cure rates exceeding 95% for benign, localized tumours. [4,25] Localization is achieved through a combination of cross-sectional imaging (CT/MRI), functional imaging (68Ga-DOTATATE PET), and endoscopic ultrasound (EUS), which has the highest sensitivity for small pancreatic lesions. [10,30,31]

Medical management with diazoxide or somatostatin analogues is reserved for patients who are not surgical candidates or have metastatic disease. [15,17,23] Targeted therapies such as everolimus are used in advanced or metastatic cases. [35]

---

Clinical Pearls

Whipple's Triad (Allen Oldfather Whipple, 1938): The diagnostic cornerstone. [18]

1. Symptoms consistent with hypoglycaemia (neuroglycopenic or autonomic)
2. Documented low plasma glucose at the time of symptoms (typically less than 2.5 mmol/L or less than 45 mg/dL)
3. Relief of symptoms following glucose administration

All three components must be present to confirm that symptoms are due to hypoglycaemia.

Fasting vs. Reactive Hypoglycaemia: Insulinomas cause fasting hypoglycaemia (symptoms occur during prolonged fasting, overnight, or before meals). This contrasts with reactive hypoglycaemia, which occurs 1-3 hours post-prandially (e.g., post-gastric bypass surgery, dumping syndrome, idiopathic). [1,7]

C-Peptide is the Key to Aetiology:

• Insulinoma: ↑ Insulin, ↑ C-Peptide (endogenous production)
• Exogenous Insulin (factitious): ↑ Insulin, ↓ C-Peptide (no endogenous C-peptide co-secreted)
• Sulfonylurea Overdose: ↑ Insulin, ↑ C-Peptide (stimulates endogenous release) → requires sulfonylurea screen [27,29]

Proinsulin is cleaved into equimolar amounts of insulin and C-peptide, so endogenous hyperinsulinaemia always elevates both. [27,29]

Tiny Tumours, Big Challenge: Most insulinomas are less than 2 cm and difficult to visualize on conventional CT/MRI. [7,10] Endoscopic ultrasound (EUS) is the most sensitive non-invasive localization technique, with sensitivity > 90%. [10,11] Intraoperative ultrasound further improves detection during surgery. [4]

MEN1 Screening: Always consider MEN1 in patients with:

• Age less than 40 years at diagnosis
• Multiple pancreatic lesions
• Family history of endocrine tumours (parathyroid, pituitary, pancreatic)
• Screen for concomitant hyperparathyroidism (calcium), pituitary adenoma (prolactin). [7,8,9]

"Rule of 10s" (approximate):

• 10% malignant
• 10% multiple
• 10% associated with MEN1
• 90% in pancreas (rarely ectopic in duodenum/jejunum) [7,25]

---

2. Epidemiology

Incidence and Prevalence

• Incidence: 1-4 cases per million per year. Insulinoma is rare but the most common functioning pancreatic NET. [1,7,25]
• Prevalence: Estimated 1-2 per 250,000 population.
• Age: Can occur at any age. Peak incidence in 4th-6th decade (40-60 years). [7]
• Sex: Slight female predominance (F:M ratio ~1.4:1). [7]

Geographic Distribution

• No significant geographic or ethnic variation reported.
• Data predominantly from Western populations; incidence in Asia likely similar but underreported.

Tumour Characteristics

Exam Detail: ### Associations

1. Multiple Endocrine Neoplasia Type 1 (MEN1)

• 5-10% of insulinomas occur in the context of MEN1 syndrome. [7,8]
• MEN1 is an autosomal dominant disorder caused by germline mutations in the MEN1 gene (chromosome 11q13), encoding the tumour suppressor protein menin. [8]
• Classic triad: Parathyroid adenoma (hyperparathyroidism, 90%), Pituitary adenoma (30%), Pancreatic NET (30-80%, including insulinoma, gastrinoma). [8]
• Insulinomas in MEN1:
  • Tend to be multiple and smaller
  • May be multifocal throughout the pancreas
  • Recurrence risk higher after surgery
  • Earlier age of onset (often less than 40 years) [8,9]
• Screening: Family history, genetic testing, biochemical screening for hyperparathyroidism (calcium, PTH).

2. Sporadic Insulinoma

• 90-95% of insulinomas are sporadic, with no identifiable genetic syndrome. [7]
• Typically solitary, unifocal, and curable with surgery.

---

3. Aetiology and Pathophysiology

Molecular Pathogenesis

Tumour Origin

• Insulinomas arise from pancreatic beta-cells within the Islets of Langerhans. [7,25]
• Beta-cells normally secrete insulin in response to elevated blood glucose, amino acids, and incretin hormones.
• Loss of normal glucose feedback is the hallmark of insulinoma: insulin secretion becomes autonomous and inappropriate. [7]

Genetic Alterations

Exam Detail: ##### Sporadic Insulinomas

• Majority have no identifiable driver mutation in common oncogenes.
• Recent genomic studies identify mutations in:
  • "YY1 (Yin Yang 1 transcription factor): ~30% of sporadic insulinomas [25]"
  • "MEN1 gene: somatic mutations in ~20% of sporadic cases [25]"
  • Rare mutations in mTOR pathway genes (TSC2, PTEN)

MEN1-Associated Insulinomas

• Germline MEN1 mutation (chromosome 11q13) results in loss of menin function. [8]
• Menin regulates gene transcription and chromatin remodeling; loss leads to unchecked cell proliferation in endocrine tissues.
• Second hit (loss of heterozygosity) results in clonal expansion and tumour formation.

---

Pathophysiology of Hypoglycaemia

The clinical manifestations of insulinoma result from autonomous, unregulated insulin secretion.

1. Normal Glucose Homeostasis (Fasting State)

In healthy individuals during fasting:

• Blood glucose falls → Insulin secretion suppresses
• Counter-regulatory hormones rise (glucagon, cortisol, growth hormone, epinephrine)
• Hepatic gluconeogenesis and glycogenolysis maintain normoglycaemia (4.0-5.5 mmol/L)
• Ketogenesis provides alternative fuel for the brain

2. Insulinoma-Induced Derangement

1. Autonomous Insulin Secretion: Tumour releases insulin independent of blood glucose levels. Normal negative feedback is lost. [7]

2. Suppression of Hepatic Glucose Output: Insulin inhibits:

   • Glycogenolysis (breakdown of glycogen)
   • Gluconeogenesis (synthesis of glucose from amino acids, lactate, glycerol)

3. Increased Peripheral Glucose Uptake: Insulin drives glucose uptake into:

   • Skeletal muscle (GLUT4 translocation)
   • Adipose tissue

4. Suppression of Lipolysis and Ketogenesis: Insulin inhibits hormone-sensitive lipase, preventing release of free fatty acids and subsequent ketone body production. Low beta-hydroxybutyrate is a diagnostic clue (distinguishes from ketotic hypoglycaemia). [1,3]

5. Progressive Hypoglycaemia: Without dietary glucose input (fasting), blood glucose falls progressively. Symptoms manifest when glucose less than 3.0 mmol/L (less than 54 mg/dL), especially neuroglycopenia when less than 2.5 mmol/L (less than 45 mg/dL). [1,7]

---

Why C-Peptide and Proinsulin Matter

Understanding the insulin biosynthesis pathway is critical for differential diagnosis. [27,29]

Beta-Cell Insulin Production:

   PREPROINSULIN (gene transcription)
           ↓
   PROINSULIN (endoplasmic reticulum)
           ↓
   Cleavage by prohormone convertases
           ↓
   INSULIN + C-PEPTIDE (equimolar secretion)
           ↓
   Co-packaged in secretory granules
           ↓
   Released into circulation (1:1 molar ratio)

Diagnostic Interpretation

Clinical Pearl: Factitious Hypoglycaemia: Consider in healthcare workers, patients with psychiatric disorders, or those with access to insulin. Clue: Inappropriately elevated insulin with suppressed C-peptide (less than 0.2 ng/mL). Occasionally, patients inject insulin analogues (e.g., lispro, aspart), which may not be detected on standard insulin assays—specific assays for analogues may be required. [27]

---

4. Clinical Presentation

Symptoms of Hypoglycaemia

Symptoms are caused by:

1. Neuroglycopenia (brain glucose deprivation)
2. Autonomic activation (catecholamine-mediated counter-regulation)

Symptom onset typically occurs when plasma glucose falls below 3.0 mmol/L (54 mg/dL), with severe neuroglycopenia at less than 2.5 mmol/L (45 mg/dL). [1,7]

---

A. Neuroglycopenic Symptoms (Brain Glucose Deprivation)

The brain is obligately glucose-dependent and cannot use fatty acids for fuel (can use ketones, but insulinoma suppresses ketogenesis).

Clinical Pearl: Diagnostic Delay: Patients are often misdiagnosed for years with:

• Epilepsy (attributed to seizures without recognizing hypoglycaemia as the trigger)
• Psychiatric illness (bizarre behaviour, aggression, emotional lability)
• Dementia (cognitive impairment, especially in elderly)
• Stroke/TIA (focal deficits that resolve with glucose)

Always consider insulinoma in patients with recurrent, stereotyped neurological symptoms relieved by eating. [1,7]

---

B. Autonomic (Adrenergic) Symptoms

Result from catecholamine release in response to hypoglycaemia.

• Autonomic symptoms often precede neuroglycopenia, providing a warning. However, chronic recurrent hypoglycaemia can lead to hypoglycaemia unawareness (blunted autonomic response), increasing risk of severe neuroglycopenia without warning. [1]

---

Timing and Triggers

Exam Detail: ### Adaptive Behaviours

Patients often unconsciously develop strategies to avoid hypoglycaemia:

• Frequent snacking, especially carbohydrate-rich foods
• Eating immediately upon waking or before bed
• Avoiding fasting or skipping meals
• Weight gain is common due to frequent eating [7]

Clinicians should specifically ask: "Do you feel unwell if you skip breakfast or go without food for several hours? Do you keep snacks by your bedside?"

---

Physical Examination

• During a hypoglycaemic episode: Sweating, tachycardia, confusion, tremor, pallor. May be unresponsive or seizing if severe.
• Between episodes: Examination is typically normal.
• Weight gain may be noted (frequent eating to prevent symptoms).
• No palpable abdominal mass (tumours are small).

---

Duration Before Diagnosis

• Mean delay: 2-5 years from symptom onset to diagnosis. [7]
• Symptoms are often attributed to other causes initially.
• Diagnosis requires high index of suspicion and documentation of Whipple's triad.

---

5. Differential Diagnosis

Causes of Hypoglycaemia in Non-Diabetic Adults

Exam Detail: Hypoglycaemia is defined as plasma glucose less than 3.0 mmol/L (less than 54 mg/dL). [1] In healthy adults, this is rare; the presence of Whipple's triad warrants investigation.

---

Comparison Table: Insulinoma vs. Key Differentials

---

6. Investigations

Diagnostic Approach

The diagnosis of insulinoma requires two steps:

1. Biochemical confirmation of endogenous hyperinsulinaemic hypoglycaemia
2. Radiological localization of the tumour

---

Step 1: Biochemical Diagnosis

A. 72-Hour Supervised Fasting Test (Gold Standard) [1,2,3]

Indication: Suspected insulinoma (recurrent Whipple's triad).

Protocol:

• Setting: Inpatient, supervised by nursing/medical staff.
• Duration: Fast for up to 72 hours or until symptoms of hypoglycaemia develop with documented plasma glucose less than 2.5 mmol/L (less than 45 mg/dL). [1,2,3]
• Permitted: Water, non-caloric, non-caffeinated beverages.
• Prohibited: All food, caloric drinks. Patients should remain active during the day (not bedbound, to provoke hypoglycaemia).

Monitoring:

• Measure capillary glucose every 6 hours initially, then every 1-2 hours when glucose falls below 3.3 mmol/L (60 mg/dL).
• When capillary glucose ≤2.5 mmol/L (45 mg/dL) AND symptoms are present, draw blood immediately for:

Critical Sample (at time of symptomatic hypoglycaemia):

• Plasma glucose (laboratory, not capillary)
• Insulin
• C-peptide
• Proinsulin
• Beta-hydroxybutyrate (or total ketones)
• Sulfonylurea/meglitinide screen (urine or plasma)
• Optional: Insulin antibodies (if exogenous insulin suspected)

Termination Criteria:

• Plasma glucose ≤2.5 mmol/L with symptoms → Take samples and terminate fast with oral glucose or IV dextrose
• 72 hours elapsed without hypoglycaemia → Insulinoma unlikely; consider other diagnoses

Exam Detail: Timing of Hypoglycaemia:

• ~70% develop hypoglycaemia within 24 hours [2,3]
• ~90% within 48 hours [1,2]
• ~95% within 72 hours [1,3]

Some centres use a 48-hour fast as an alternative, which has high sensitivity with shorter duration. [2]

---

B. Diagnostic Criteria for Insulinoma [1,7,27,29]

At the time of documented hypoglycaemia (glucose ≤2.5 mmol/L / ≤45 mg/dL):

Interpretation:

• Insulinoma: All criteria met. Endogenous hyperinsulinaemic hypoglycaemia.
• Exogenous Insulin: Insulin elevated, C-peptide low (less than 0.6 ng/mL).
• Sulfonylurea: Insulin and C-peptide elevated, positive sulfonylurea screen.

Clinical Pearl: Why Beta-Hydroxybutyrate?

During fasting, the normal response to hypoglycaemia (when insulin is suppressed) includes:

• Lipolysis → Free fatty acids → Hepatic ketogenesis → Ketones (beta-hydroxybutyrate, acetoacetate) provide alternative brain fuel

In insulinoma, insulin remains elevated despite hypoglycaemia, which:

• Inhibits lipolysis → No FFA → No ketone production
• Result: Low beta-hydroxybutyrate (less than 2.7 mmol/L) despite prolonged fasting and hypoglycaemia [1,3]

This distinguishes insulinoma from ketotic hypoglycaemia (e.g., alcohol-induced, starvation, GH/cortisol deficiency), where ketones are elevated.

---

C. Calculated Insulin:Glucose Ratio

Some centres calculate:

• Insulin (μU/mL) : Glucose (mg/dL) ratio

A ratio > 0.3 during hypoglycaemia suggests inappropriate insulin secretion. However, this is not universally reliable and should not replace absolute insulin, C-peptide, and proinsulin measurements. [28]

---

Step 2: Tumour Localization

Once biochemical diagnosis is confirmed, the next step is locating the insulinoma to guide surgical planning. [7,10,25]

---

A. Cross-Sectional Imaging

1. CT Pancreas (Multiphasic Contrast-Enhanced) [25]

• Technique: Thin-slice CT with arterial, pancreatic parenchymal, and portal venous phases.
• Findings: Insulinomas are hypervascular and enhance brightly on arterial phase.
• Sensitivity: 40-70% (limited for tumours less than 1-2 cm). [10,25]
• Advantages: Widely available, good for surgical planning (vascular anatomy).
• Disadvantages: May miss small lesions.

2. MRI Pancreas (T1, T2, Dynamic Contrast) [25]

• Findings: Insulinomas are typically T2 hyperintense (bright on T2-weighted sequences) relative to pancreatic parenchyma. Enhance on post-contrast arterial phase.
• Sensitivity: 50-80%. [10,25]
• Advantages: Superior soft tissue contrast, no ionizing radiation.
• Disadvantages: Longer acquisition time, lower spatial resolution than CT.

---

B. Endoscopic Ultrasound (EUS) [10,11]

• Technique: Endoscopic probe with high-frequency ultrasound transducer positioned adjacent to the pancreas via the stomach/duodenum.
• Sensitivity: 85-95% for pancreatic insulinomas. [10]
• Most sensitive modality for detecting small (less than 2 cm) pancreatic lesions. [10,11]
• Advantages:
  • Highest sensitivity
  • Allows fine-needle aspiration (FNA) for cytology/histology if needed
  • Differentiates solid vs. cystic lesions
• Disadvantages: Operator-dependent, invasive, requires sedation/anaesthesia.

Exam Detail: EUS Findings:

• Insulinomas appear as well-defined, hypoechoic (dark), round lesions within the pancreas.
• Typically homogeneous.
• Can assess relationship to pancreatic duct (important for surgical planning—enucleation vs. resection). [10,11]

---

C. Functional Imaging: 68Ga-DOTATATE PET/CT [30,31]

• Principle: Insulinomas (like most well-differentiated NETs) express somatostatin receptors (SSTR2). 68Ga-DOTATATE is a somatostatin analogue that binds SSTR2.
• Sensitivity: 50-70% for insulinomas (lower than for other pancreatic NETs, as insulinomas variably express SSTR2). [30,31]
• Advantages:
  • Whole-body imaging (detects ectopic or metastatic disease)
  • Useful in MEN1 (multiple tumours) [30]
  • Helpful for malignant/metastatic insulinoma staging [31]
• Disadvantages: Not all insulinomas are SSTR2-positive; negative scan does not exclude diagnosis.

Exam Detail: Alternative Functional Imaging:

• 68Ga-Exendin-4 PET: Targets GLP-1 receptors, which are highly expressed on beta-cells. Very high sensitivity (> 95%) for insulinomas but limited availability. [7,25]
• 111In-Octreotide Scintigraphy (Octreoscan): Older SSTR imaging; largely replaced by DOTATATE PET (higher resolution). [22]

---

D. Selective Arterial Calcium Stimulation with Hepatic Venous Sampling (ASVS) [19,20,21]

• Indication: Biochemically confirmed insulinoma with negative or equivocal non-invasive imaging (occult insulinoma). [19,20]
• Technique:
  • Invasive catheter-based procedure.
  • Selective intra-arterial calcium injection into pancreatic arterial branches (splenic, gastroduodenal, superior mesenteric arteries).
  • Calcium stimulates insulin release from the perfused region.
  • Simultaneous hepatic venous sampling for insulin levels.
  • A ≥2-fold rise in hepatic venous insulin after calcium injection into a specific artery regionalizes the insulinoma to the vascular territory of that artery (head vs. body vs. tail). [19,20,21]
• Sensitivity: > 90% for regionalization (does not pinpoint exact location but narrows the surgical field). [19,20]
• Disadvantages: Invasive, requires interventional radiology expertise, does not provide anatomical localization.

Clinical Pearl: When to Use Calcium Stimulation Test?

• Biochemically proven insulinoma
• CT, MRI, and EUS all negative or inconclusive
• Patient is a surgical candidate
• Goal: Guide the surgeon to the correct pancreatic region (head/body/tail) for intraoperative exploration [19,20]

---

E. Intraoperative Ultrasound (IOUS)

• Technique: Ultrasound probe applied directly to the pancreas during surgery.
• Sensitivity: 85-95% for detecting small pancreatic lesions, even if not seen preoperatively. [4]
• Advantages: Allows real-time localization during surgery, especially for small or deep tumours.
• Standard of care during insulinoma surgery. [4]

---

Localization Strategy (Step-Wise) [7,25]

BIOCHEMICALLY CONFIRMED INSULINOMA
           ↓
[1] CT or MRI Pancreas (Triphasic)
           ↓
    Lesion Identified?
           ↓
     YES → Proceed to surgery (with IOUS)
           ↓
     NO → [2] Endoscopic Ultrasound (EUS)
           ↓
    Lesion Identified?
           ↓
     YES → Proceed to surgery (with IOUS)
           ↓
     NO → [3] 68Ga-DOTATATE PET/CT
           ↓
    Lesion Identified?
           ↓
     YES → Proceed to surgery (with IOUS)
           ↓
     NO → [4] Selective Arterial Calcium Stimulation
           ↓
    Regional Localization → Surgery with IOUS
           ↓
    Still Negative → Repeat imaging in 6-12 months
    (Consider blind distal pancreatectomy if symptoms severe and uncontrolled)

Exam Detail: Occult Insulinomas: Approximately 5-10% of insulinomas are not detected on preoperative imaging, even with EUS and functional imaging. [7] In such cases:

• Calcium stimulation test can regionalize the tumour.
• Intraoperative ultrasound and palpation by an experienced surgeon often localize the tumour during surgery. [4]
• Rarely, if completely occult and symptoms are refractory, blind distal pancreatectomy (removing body and tail, where 60% of insulinomas occur) may be considered. [7]

---

Other Investigations

Screening for MEN1 [8,9]

Indications:

• Age less than 40 years at diagnosis
• Multiple pancreatic lesions
• Family history of endocrine tumours
• Concomitant hyperparathyroidism

Tests:

• Serum calcium, PTH (primary hyperparathyroidism)
• Prolactin (pituitary adenoma)
• Genetic testing: MEN1 gene sequencing (if criteria met)
• Family screening: First-degree relatives if MEN1 confirmed

---

7. Management

Goals of Treatment

1. Achieve euglycaemia and relieve symptoms
2. Curative resection of the tumour (if feasible)
3. Prevent recurrence
4. Manage metastatic disease (if malignant)

---

Management Algorithm

CONFIRMED INSULINOMA + LOCALIZED ON IMAGING
           ↓
    ASSESS SURGICAL FITNESS
           ↓
      Operable?
    ┌─────────┴─────────┐
  YES                   NO
   ↓                     ↓
SURGICAL RESECTION   MEDICAL MANAGEMENT
(Curative Intent)     (Symptom Control)
   ↓                     ↓
- Enucleation        - Diazoxide
- Distal             - Octreotide
  Pancreatectomy     - Frequent meals
- Pancreatico-       - Everolimus
  duodenectomy          (if advanced)
  (rare)
   ↓
INTRAOPERATIVE
ULTRASOUND
   ↓
HISTOLOGY
   ↓
Benign → Cure (> 95%)
Malignant → Staging, Adjuvant therapy
   ↓
LONG-TERM FOLLOW-UP
(Annual imaging for 5 years)
   ↓
SCREEN FOR MEN1
(if less than 40yo, multiple, or FHx)

---

A. Surgical Management (Definitive Treatment) [4,5,25]

Surgery is the only curative treatment and should be offered to all operable patients with localized disease. [4,25]

Surgical Options

The choice of operation depends on:

• Tumour location (head, body, tail)
• Size
• Proximity to pancreatic duct
• Single vs. multiple tumours

---

1. Enucleation [4,5]

• Indication: Small (less than 2 cm), benign, superficial tumours > 2-3 mm from the main pancreatic duct.
• Technique: "Shell out" the tumour, preserving surrounding pancreatic parenchyma.
• Advantages:
  • Parenchyma-sparing (minimizes risk of diabetes)
  • Shorter operative time
  • Lower morbidity
• Disadvantages: Risk of pancreatic fistula (~10-20%). [4]
• Approach: Open, laparoscopic, or robotic. [32,33,34]

---

2. Distal Pancreatectomy ± Splenectomy [4,5,25]

• Indication: Tumours in the body or tail of the pancreas.
• Technique: Resection of pancreatic body/tail. Spleen may be preserved if technically feasible.
• Cure Rate: > 95% for benign insulinoma. [4]
• Complications:
  • Pancreatic fistula (10-20%)
  • Diabetes mellitus (if extensive resection; 5-10%)
  • Splenic vein thrombosis (if spleen-preserving)
• Approach: Increasingly performed laparoscopically or robotically. [32,33,34]

Exam Detail: Laparoscopic vs. Robotic Surgery:

• Laparoscopic distal pancreatectomy and enucleation are now standard for suitable lesions. [33,34]
• Robotic approach offers improved dexterity and 3D visualization, particularly for enucleation of deep or head lesions. [32]
• Minimally invasive approaches have comparable oncological outcomes with shorter hospital stay and faster recovery. [32,34]

---

3. Pancreaticoduodenectomy (Whipple Procedure) [4,5]

• Indication: Tumours in the head of the pancreas that cannot be enucleated (e.g., close to pancreatic duct, large, or malignant with lymph node involvement).
• Technique: Resection of pancreatic head, duodenum, gallbladder, distal bile duct; reconstruction with pancreaticojejunostomy, hepaticojejunostomy, gastrojejunostomy.
• Morbidity: Significant (delayed gastric emptying, pancreatic fistula, diabetes, exocrine insufficiency). [4]
• Mortality: 1-3% in high-volume centres. [4]
• Reserved for: Tumours not amenable to enucleation or malignant disease.

---

4. Intraoperative Ultrasound (IOUS) [4]

• Mandatory during insulinoma surgery.
• Allows real-time localization, even if tumour was not seen on preoperative imaging.
• Guides surgical approach (enucleation vs. resection).
• Sensitivity > 90%. [4]

---

5. Outcomes

Clinical Pearl: Post-Operative Glucose Monitoring:

• Immediately after insulinoma resection, blood glucose typically rises (removal of insulin source).
• Monitor for hyperglycaemia in the first 24-48 hours (may require insulin temporarily).
• Monitor for recurrent hypoglycaemia (suggests incomplete resection, multiple tumours, or metastases). [4]

---

B. Medical Management [15,17,23,35]

Indications:

• Preoperative stabilization (while awaiting surgery)
• Inoperable patients (high surgical risk, comorbidities)
• Metastatic/unresectable disease
• Recurrent disease

---

1. Diazoxide [15,17]

• Mechanism: Opens ATP-sensitive K+ channels on beta-cells → Hyperpolarization → Inhibits insulin secretion.
• Dose: 150-400 mg/day (divided doses, with meals).
• Efficacy: Controls hypoglycaemia in 50-60% of patients. [15,17]
• Side Effects:
  • Fluid retention, oedema (may require diuretics; thiazide paradoxically enhances diazoxide effect)
  • Hirsutism (particularly distressing in women)
  • Nausea, hyperuricaemia
• Monitoring: Glucose levels, weight, fluid status.

Exam Detail: Diazoxide in Long-Term Management:

• A case report describes successful medical management with diazoxide for 27 years in a patient unfit for surgery. [15]
• However, long-term use is limited by side effects and potential tachyphylaxis (loss of efficacy over time). [15,17]

---

2. Somatostatin Analogues (Octreotide, Lanreotide) [17,23]

• Mechanism: Bind somatostatin receptors (SSTR2) → Inhibit insulin secretion.
• Efficacy: Variable (40-60% response). Not all insulinomas express SSTR2. [23]
• Predictive Factor: Positive 68Ga-DOTATATE PET scan predicts better response to somatostatin analogues. [23,30]
• Formulations:
  • "Short-acting Octreotide: 50-100 mcg SC TID"
  • "Long-acting Octreotide LAR: 20-30 mg IM monthly"
  • "Lanreotide Autogel: 90-120 mg SC monthly"
• Side Effects: Diarrhoea, abdominal cramps, gallstones, nausea.
• Paradoxical Worsening: Rarely, octreotide can worsen hypoglycaemia (inhibits glucagon and growth hormone more than insulin in some patients). [23]

---

3. Frequent Feeding and Glucose Monitoring

• Principle: Maintain euglycaemia by frequent carbohydrate-rich meals/snacks.
• Practical: 6-8 small meals/day, bedtime snack, continuous glucose monitoring (CGM).
• Adjunct: IV dextrose infusion (for severe, refractory hypoglycaemia in hospitalized patients).

---

4. Targeted Therapies (Metastatic/Advanced Disease) [35]

Everolimus (mTOR Inhibitor)

• Indication: Advanced, unresectable, or metastatic pancreatic NETs.
• Mechanism: Inhibits mTOR pathway → Reduces cell proliferation.
• Dose: 10 mg PO daily.
• Efficacy: Prolongs progression-free survival (PFS ~11 months vs. 4 months placebo) in RADIANT-3 trial (all pancreatic NETs, not specific to insulinoma). [35]
• Side Effects: Stomatitis, rash, diarrhoea, hyperglycaemia, pneumonitis, immunosuppression.

Sunitinib (Tyrosine Kinase Inhibitor)

• Indication: Advanced pancreatic NETs.
• Mechanism: Inhibits VEGFR, PDGFR → Anti-angiogenic.
• Efficacy: Improved PFS in pancreatic NETs.
• Side Effects: Hypertension, hand-foot syndrome, diarrhoea, hypothyroidism, myelosuppression.

---

5. Peptide Receptor Radionuclide Therapy (PRRT)

• Indication: Metastatic, SSTR-positive NETs (if positive on DOTATATE PET).
• Agent: 177Lu-DOTATATE (Lutathera).
• Mechanism: Targeted radiotherapy to SSTR-expressing tumour cells.
• Efficacy: Improved PFS and overall survival in midgut NETs (NETTER-1 trial). Data for insulinoma limited but promising. [25]
• Availability: Requires specialized centres.

---

6. Cytotoxic Chemotherapy

• Indication: Poorly differentiated, high-grade (Ki-67 > 20%) pancreatic NETs.
• Regimens: Platinum-based (cisplatin/carboplatin + etoposide), temozolomide + capecitabine.
• Efficacy: Limited in well-differentiated insulinomas; reserved for aggressive, high-grade tumours. [25]

---

C. Management of Malignant Insulinoma [13,14,25]

Definition: Presence of metastases (most commonly liver, lymph nodes) or unequivocal vascular/adjacent organ invasion. [13,14]

Incidence: 5-10% of insulinomas are malignant. [13,14]

Management Strategy:

1. Surgical Debulking: If feasible, resection of primary and accessible metastases (improves symptom control). [13,14]
2. Liver-Directed Therapy: For liver metastases:
   • Radiofrequency ablation (RFA)
   • Transarterial embolization (TAE) or chemoembolization (TACE)
3. Systemic Therapy:
   • Everolimus, Sunitinib [35]
   • PRRT (if SSTR-positive) [25]
   • Chemotherapy (if high-grade)
4. Symptomatic Control: Diazoxide, octreotide (if SSTR-positive), frequent feeding. [15,17,23]

Prognosis:

• 5-year survival: 50-60% for metastatic insulinoma. [13,14]
• Better than other malignant pancreatic NETs (e.g., gastrinoma), possibly due to lower tumour burden required for symptomatology (earlier detection). [13]

Exam Detail: Case Report: Metastatic Insulinoma Outcomes: A recent study of metastatic insulinomas in the current era (with modern therapies) showed:

• Median overall survival: 9.1 years
• Better outcomes with surgical debulking + systemic therapy vs. systemic therapy alone
• Everolimus and PRRT improved PFS [13]

---

8. Complications

A. Complications of Hypoglycaemia (Untreated Insulinoma)

Clinical Pearl: Driving and Insulinoma:

• In the UK, patients with recurrent hypoglycaemia must inform the DVLA.
• Driving is typically prohibited until hypoglycaemia is controlled (post-surgery or with effective medical therapy). [DVLA guidance]

---

B. Complications of Surgery [4,5]

---

C. Complications of Medical Therapy

---

9. Prognosis and Outcomes

Benign Insulinoma (90-95%)

---

Malignant Insulinoma (5-10%)

---

Follow-Up [7,25]

Post-Operative Surveillance:

• Sporadic, Solitary, Benign Insulinoma:

  • Clinical review at 3, 6, 12 months, then annually for 5 years
  • Fasting glucose, HbA1c (monitor for diabetes post-pancreatectomy)
  • Imaging (CT/MRI) at 6-12 months, then as clinically indicated

• MEN1-Associated:

  • Lifelong annual surveillance (biochemistry + imaging)
  • Screen for other MEN1 manifestations (parathyroid, pituitary)
  • Genetic counselling and family screening [8]

• Malignant/Metastatic:

  • 3-6 monthly imaging (CT/MRI)
  • Monitor chromogranin A, fasting glucose, insulin
  • DOTATATE PET annually (if SSTR-positive)

---

10. Evidence and Guidelines

Key Guidelines

---

Landmark Evidence

Exam Detail: #### 1. Whipple's Triad (1938) [18]

• Allen Oldfather Whipple, American surgeon, first described the diagnostic triad while investigating hypoglycaemic patients with pancreatic tumours.
• Remains the diagnostic cornerstone nearly 90 years later. [18]

2. The 72-Hour Fast (1999-2000) [2,3]

• Service FJ et al. (Mayo Clinic): Established 72h supervised fast as the gold standard diagnostic test.
• Demonstrated 95% sensitivity for detecting insulinoma within 72 hours. [2,3]
• Hirshberg et al. (2000): Proposed 48-hour fast as an alternative with comparable sensitivity (~90%). [2]

3. EUS for Localization (2018) [10]

• Wang et al. meta-analysis: Pooled sensitivity of EUS for insulinoma localization = 92.6%, superior to CT (56%) and MRI (66%).
• Established EUS as the most sensitive non-invasive localization technique. [10]

4. Calcium Stimulation Test (2016-2021) [19,20,21]

• Morera et al. (2016), Hatoko et al. (2020), Kim et al. (2021): Selective arterial calcium stimulation achieves > 90% regionalization for occult insulinomas.
• Remains valuable when non-invasive imaging is negative. [19,20,21]

5. Surgical Outcomes (2021) [4]

• de Carbonnières et al.: 30-year experience with 160 insulinomas. Cure rate > 95%. Laparoscopic approach safe and effective.
• Enucleation preferred for small, benign lesions. [4]

6. Malignant Insulinoma Survival (2024) [13]

• Masharani et al.: Median overall survival for metastatic insulinoma in the modern era = 9.1 years.
• Surgical debulking + systemic therapy (everolimus, PRRT) improved outcomes. [13]

7. ENETS 2023 Guidance [25]

• Hofland et al.: Comprehensive evidence-based guidelines for functioning pancreatic NETs, including insulinoma.
• Emphasizes 72h fast, EUS, surgical resection, and PRRT for SSTR+ metastatic disease. [25]

---

11. Examination Focus

High-Yield Viva Topics

1. Diagnosis

Q: A 45-year-old woman presents with recurrent episodes of confusion and sweating before breakfast, relieved by eating. What is the most likely diagnosis and how would you confirm it?

Model Answer:

• Likely Diagnosis: Insulinoma (fasting hypoglycaemia with Whipple's triad).
• Whipple's Triad: (1) Symptoms of hypoglycaemia, (2) Documented low glucose at time of symptoms, (3) Relief with glucose.
• Confirmatory Test: 72-hour supervised fast. Measure plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and sulfonylurea screen at time of symptomatic hypoglycaemia (less than 2.5 mmol/L).
• Diagnostic Criteria: Insulin ≥3 μU/mL, C-peptide ≥0.6 ng/mL, proinsulin ≥5 pmol/L, beta-hydroxybutyrate less than 2.7 mmol/L, negative sulfonylurea screen. [1,7,27]

---

2. C-Peptide Interpretation

Q: A patient has hypoglycaemia with elevated insulin. C-peptide is low. What is the diagnosis?

Model Answer:

• Diagnosis: Factitious hypoglycaemia (exogenous insulin administration).
• Reasoning: Endogenous insulin production (from beta-cells) co-secretes insulin and C-peptide in equimolar amounts. Exogenous insulin (injected) contains no C-peptide, so C-peptide remains suppressed. [27]
• Contrast with Insulinoma: Insulinoma → ↑ Insulin + ↑ C-peptide (endogenous production). [27,29]
• Further Investigation: Search for insulin vials, check insulin antibodies (if animal insulin), consider psychiatric evaluation.

---

3. Localization Imaging

Q: CT and MRI fail to localize an insulinoma. What is the next step?

Model Answer:

• Next Step: Endoscopic Ultrasound (EUS). [10,11]
• Rationale: EUS has the highest sensitivity (> 90%) for small pancreatic lesions, superior to CT/MRI. [10]
• Alternative: 68Ga-DOTATATE PET/CT (if EUS unavailable or inconclusive).
• If Still Negative: Selective arterial calcium stimulation test to regionalize the tumour (head vs. body vs. tail). [19,20]
• Intraoperative: Intraoperative ultrasound during surgery often localizes even occult tumours. [4]

---

4. MEN1 Association

Q: A 35-year-old man with recurrent kidney stones is found to have an insulinoma. What syndrome should you consider and how would you screen for it?

Model Answer:

• Syndrome: MEN1 (Multiple Endocrine Neoplasia Type 1). [7,8]
• Clue: Kidney stones suggest hyperparathyroidism (parathyroid adenoma, most common MEN1 manifestation). [8]
• MEN1 Triad: Parathyroid adenoma (90%), Pituitary adenoma (30%), Pancreatic NET (30-80%). [8]
• Screening:
  • "Biochemistry: Calcium, PTH, prolactin, fasting glucose, gastrin"
  • "Imaging: MRI pancreas, MRI pituitary"
  • "Genetic testing: MEN1 gene sequencing [8]"
• Family History: Autosomal dominant inheritance; screen first-degree relatives. [8]

---

5. Surgical Approach

Q: What are the surgical options for a 1.5 cm insulinoma in the tail of the pancreas?

Model Answer:

• Options: [4,5]
  1. Enucleation (if superficial, > 3 mm from pancreatic duct)
     • Parenchyma-sparing
     • Risk: Pancreatic fistula (~10-20%)
  2. Distal Pancreatectomy ± splenectomy
     • Curative (> 95%)
     • Risk: Diabetes (if > 50% resection), pancreatic fistula
  3. Laparoscopic vs. Open: Minimally invasive approach preferred (shorter hospital stay, comparable outcomes). [32,33,34]
• Intraoperative Ultrasound: Mandatory for localization. [4]
• Spleen Preservation: Attempt if technically feasible (avoid lifelong risk of overwhelming post-splenectomy infection). [4]

---

6. Medical Management

Q: An elderly patient with insulinoma is deemed unfit for surgery. What medical options are available?

Model Answer:

• First-Line: Diazoxide 150-400 mg/day. [15,17]
  • "Mechanism: Opens K-ATP channels → inhibits insulin secretion"
  • "Efficacy: 50-60% response"
  • "Side effects: Oedema, hirsutism"
• Second-Line: Somatostatin analogues (Octreotide, Lanreotide) [17,23]
  • Variable efficacy (40-60%)
  • "Predictive: Positive DOTATATE PET scan"
  • "Risk: Paradoxical worsening in some patients"
• Supportive: Frequent carbohydrate-rich meals, continuous glucose monitoring
• Advanced Disease: Everolimus, Sunitinib, PRRT (if SSTR+). [35]

---

7. Malignant Insulinoma

Q: What defines malignant insulinoma and what is the prognosis?

Model Answer:

• Definition: Presence of metastases (liver, lymph nodes) or unequivocal local invasion. [13,14]
• Incidence: 5-10% of insulinomas. [13,14]
• Prognosis: 5-year survival ~50-60%; median survival 9.1 years (modern therapy). [13]
• Management:
  • Surgical debulking (if feasible) [13,14]
  • Liver-directed therapy (RFA, TACE)
  • "Systemic: Everolimus, Sunitinib, PRRT (if SSTR+) [35]"
  • "Symptomatic: Diazoxide, Octreotide [15,23]"
• Better prognosis than other malignant pancreatic NETs (earlier detection due to symptoms). [13]

---

Common OSCE/Clinical Exam Scenarios

Station: History Taking

Scenario: 52-year-old woman with recurrent "funny turns" in the morning.

Key Points to Elicit:

• Timing: Fasting vs. post-prandial? Overnight, before breakfast?
• Symptoms: Sweating, tremor, confusion, odd behaviour, seizures?
• Relieving Factors: Eating relieves symptoms?
• Frequency: How often? Progressive?
• Adaptive Behaviours: Frequent snacking? Bedside snacks? Weight gain?
• Red Flags: Loss of consciousness, road traffic accidents, seizures
• Past Medical History: Diabetes? (unlikely if hypoglycaemia, but ask about treatment)
• Family History: Endocrine tumours? Kidney stones? (MEN1)
• Social History: Occupation (healthcare worker—access to insulin?), psychiatric history

---

Station: Data Interpretation

Given:

• Plasma glucose: 2.1 mmol/L
• Insulin: 18 μU/mL
• C-peptide: 3.2 ng/mL
• Proinsulin: 22 pmol/L
• Beta-hydroxybutyrate: 0.8 mmol/L
• Sulfonylurea screen: Negative

Q: Interpret the results.

Answer:

• Hypoglycaemia (glucose 2.1 mmol/L) with:
• Inappropriately elevated insulin (should be less than 3 μU/mL during hypoglycaemia)
• Elevated C-peptide (proves endogenous source)
• Elevated proinsulin (characteristic of insulinoma)
• Suppressed beta-hydroxybutyrate (insulin inhibits ketogenesis)
• Negative sulfonylurea (excludes oral hypoglycaemic agent)
• Diagnosis: Endogenous hyperinsulinaemic hypoglycaemia, consistent with Insulinoma. [1,7,27,29]
• Next Steps: Localization imaging (CT/MRI/EUS), MEN1 screening (if less than 40yo or FHx).

---

12. Patient and Layperson Explanation

What is an Insulinoma?

An insulinoma is a rare, usually non-cancerous (benign) tumour in your pancreas—a gland behind your stomach that helps control your blood sugar. This tumour produces too much insulin, the hormone that lowers blood sugar. When your blood sugar drops too low (hypoglycaemia), you can feel sweaty, shaky, confused, or even pass out.

---

Why do I get symptoms?

Your brain relies on sugar (glucose) for energy. When insulin levels are too high, your blood sugar drops dangerously low, especially when you haven't eaten for a while (like overnight or if you skip breakfast). This lack of sugar affects your brain, causing confusion, odd behaviour, or even seizures. Eating or drinking something sugary makes you feel better quickly.

---

How is it diagnosed?

We will admit you to the hospital for a supervised fasting test. You'll fast (no food, only water) for up to 72 hours while we monitor your blood sugar and insulin levels. If your blood sugar drops but your insulin stays high, it confirms the diagnosis. We'll then do scans (CT, MRI, or a special ultrasound through your stomach) to find the tumour.

---

Is it cancer?

In about 9 out of 10 cases, no—insulinomas are benign. Only about 10% are malignant (cancerous). Even if it is cancerous, there are effective treatments available.

---

How is it treated?

Surgery is the main treatment and is usually curative. The surgeon will remove the tumour (and sometimes a small part of the pancreas). After surgery, your insulin levels return to normal, and the low blood sugar episodes stop. You'll be cured in over 95% of cases.

If surgery isn't possible (due to other health problems), we can use medications to control your blood sugar and reduce symptoms.

---

What happens after treatment?

Most patients are completely cured after surgery and lead normal lives. We'll monitor you for a few years to make sure the tumour doesn't come back (which is rare). If you have a genetic condition called MEN1, you may need lifelong monitoring, as tumours can recur or develop elsewhere.

---

Can I drive?

You should not drive while you're having low blood sugar episodes, as you could lose consciousness or become confused behind the wheel. Once you've been treated and your blood sugar is stable, you can resume driving. (In the UK, you must inform the DVLA.)

---

Will I develop diabetes?

Most patients do not develop diabetes after insulinoma treatment. However, if a large part of your pancreas is removed during surgery, there is a small risk (5-10%) of diabetes developing later. We'll monitor your blood sugar and provide treatment if needed.

---

13. References

Primary Sources and Evidence

1. Palani G, et al. Clinical Presentation and Diagnostic Approach to Hypoglycemia in Adults Without Diabetes. J Clin Endocrinol Metab. 2023. PMID: 36464132. DOI: 10.1210/clinem/dgac678

2. Hirshberg B, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85(9):3222-3226. PMID: 10999812. DOI: 10.1210/jcem.85.9.6807

3. Farahmand A, et al. Maximizing the Utility of the 72-Hour Fast in Evaluating Hypoglycemia. J Endocr Soc. 2021;5(3):bvaa200. PMID: 33475507. DOI: 10.1210/jendso/bvaa200

4. de Carbonnières A, et al. Surgical management of insulinoma over three decades. Br J Surg. 2021;108(7):842-849. PMID: 33975801. DOI: 10.1093/bjs/znab113

5. Vázquez Quintana E, et al. The surgical management of insulinoma. Rev Invest Clin. 2004;56(5):605-611. PMID: 15575328.

6. Helbing A, et al. Pancreatic Neuroendocrine Tumors. Surg Clin North Am. 2019;99(4):793-814. PMID: 28846270. DOI: 10.1016/j.suc.2019.04.014

7. Hofland J, et al. Approach to the Patient: Insulinoma. J Clin Endocrinol Metab. 2024;109(2):e469-e481. PMID: 37925662. DOI: 10.1210/clinem/dgad544

8. Adam MP, et al. Multiple Endocrine Neoplasia Type 1. GeneReviews® [Internet]. Updated 2019. PMID: 20301710.

9. Ito T, et al. Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivity for extra-pancreatic tumours. Fam Cancer. 2016;15(3):503-511. PMID: 26834963. DOI: 10.1007/s10689-016-9878-6

10. Wang H, et al. Diagnostic value of endoscopic ultrasound for insulinoma localization: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(43):e12950. PMID: 30352083. DOI: 10.1097/MD.0000000000012950

11. Zhuo F, et al. Insulinoma. StatPearls [Internet]. Updated 2025. PMID: 31335019.

12. (Not used - prostate cancer, unrelated)

13. Masharani U, et al. Metastatic insulinoma—outcomes in the current era. J Clin Endocrinol Metab. 2024;110(1):e122-e129. PMID: 39475415. DOI: 10.1210/clinem/dgae747

14. Sada A, et al. Malignant Insulinoma: A Rare Form of Neuroendocrine Tumor. Cureus. 2020;12(2):e6929. PMID: 32128613. DOI: 10.7759/cureus.6929

15. Warren AM, et al. Successful medical management of insulinoma with diazoxide for 27 years. Endocrinol Diabetes Metab Case Rep. 2020;2020:20-0140. PMID: 33434168. DOI: 10.1530/EDM-20-0140

16. (Not used - canine insulinoma)

17. Brown E, et al. Multidisciplinary management of refractory insulinomas. Clin Endocrinol (Oxf). 2018;88(5):615-622. PMID: 29205458. DOI: 10.1111/cen.13528

18. González-Vidal T, et al. Whipple of Whipple's Triad. N Engl J Med. 2023;389(24):e52. PMID: 41256744. DOI: 10.1056/NEJMicm2305799

19. Kim S, et al. Calcium Stimulation Test for Insulinoma Localization in an End-stage Renal Disease Patient on Hemodialysis. J Endocr Soc. 2021;5(3):bvaa196. PMID: 33381673. DOI: 10.1210/jendso/bvaa196

20. Morera J, et al. Preoperative localization of an insulinoma: selective arterial calcium stimulation test performance. J Clin Endocrinol Metab. 2016;101(5):2019-2023. PMID: 26577133. DOI: 10.1210/jc.2015-4080

21. Hatoko T, et al. Low-dose Selective Arterial Calcium Stimulation Test for Localizing Insulinoma: Reduction in both Calcium Dose and Sampling Points. Intern Med. 2020;59(14):1747-1753. PMID: 32611954. DOI: 10.2169/internalmedicine.4344-19

22. (Octreotide scan - general reference, not specific study)

23. Ito T, et al. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17(16):2191-2205. PMID: 27635672. DOI: 10.1080/14656566.2016.1236915

24. (Not used - canine insulinoma)

25. Hofland J, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(10):e13318. PMID: 37578384. DOI: 10.1111/jne.13318

26. Stamatakos M, et al. Insulinoma: a rare neuroendocrine pancreatic tumor. Chirurgia (Bucur). 2009;104(6):721-727. PMID: 20187464.

27. Feingold KR, et al. Insulinoma. Endotext [Internet]. Updated 2018. PMID: 25905215.

28. Li X, et al. Diagnosis of insulinoma using the ratios of serum concentrations of insulin and C-peptide to glucose. Oncol Lett. 2017;13(1):565-570. PMID: 27725372. DOI: 10.3892/ol.2016.5400

29. Vezzosi D, et al. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007;157(1):75-83. PMID: 17609405. DOI: 10.1530/EJE-07-0109

30. Liu Y, et al. 68Ga-DOTATATE PET/CT imaging for insulinoma in MEN1 patient with endogenous hyperinsulinemic hypoglycemia. Clin Nucl Med. 2022;47(10):e624-e626. PMID: 36042606. DOI: 10.1097/RLU.0000000000004327

31. Abdelkawi MM, et al. 68Ga-DOTATATE PET/CT: How is it reliable in imaging of cases having clinical suspicion of insulinoma? Nucl Med Commun. 2024;45(11):954-962. PMID: 39137605. DOI: 10.1097/MNM.0000000000001887

32. Yin ZZ, et al. Robotic versus laparoscopic surgery for sporadic benign insulinoma: Short- and long-term outcomes. Asian J Surg. 2024;47(1):263-269. PMID: 37423832. DOI: 10.1016/j.asjsur.2023.06.119

33. Mori T, et al. Laparoscopic pancreatic surgery. J Hepatobiliary Pancreat Surg. 2005;12(6):451-455. PMID: 16365817. DOI: 10.1007/s00534-005-1027-9

34. Aggeli C, et al. Laparoscopic surgery for pancreatic insulinomas: an update. Minerva Chir. 2016;71(4):276-283. PMID: 27376420.

35. Chernykh TM, et al. [Current views on the treatment of insulinoma]. Probl Endokrinol (Mosk). 2024;70(1):63-72. PMID: 38433541. DOI: 10.14341/probl13394 (Russian)

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and the latest evidence. Always consult appropriate specialists and current guidelines for patient management.

---

Document Metadata

• Word Count: ~10,800 words
• Line Count: 1,046 lines
• Target Audience: MRCP, Endocrinology Trainees, Medical Students (Finals)
• Evidence Quality: Level I-II (Systematic reviews, prospective cohort studies, expert consensus)
• Last Updated: 2026-01-06
• Next Review: 2027-01-06